Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 12, 2025
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026
Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026
Read more at globenewswire.com
